Results 221 to 230 of about 118,448 (336)

Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. [PDF]

Eur J Neurol
Staubo SC, Fuskevåg OM, Toft M, Lie IH, Alvik KMJ, Jostad P, Tingvoll SH, Lilleng H, Rosqvist K, Størset E, Odin P, Dietrichs E, Dietrichs ES.   +12 more
europepmc   +1 more source

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. [PDF]

Mov Disord, 2021
Picillo M, Phokaewvarangkul O, Poon YY, McIntyre CC, Beylergil SB, Munhoz RP, Kalia SK, Hodaie M, Lozano AM, Fasano A.   +9 more
europepmc   +1 more source

Erratum to “estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats” [Neurosci. Lett. 193 (1995) 65–67]

, 1995
Raul R. Gainetdinov, Tatyana D. Sotnikova, Tatyana V. Grekhova, K.S. Rayevsky   +3 more
openalex   +1 more source

Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. [PDF]

CNS Neurol Disord Drug Targets
Bezard E, Gray D, Kozak R, Leoni M, Combs C, Duvvuri S.   +5 more
europepmc   +1 more source

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment. [PDF]

AACE Clin Case Rep, 2021
Ali M, Mirza L.
europepmc   +1 more source

Effects of the dopamine D2 agonist, quinpirole, on time and number processing in rats [PDF]

, 2001
Angelo Santi, Romina Coppa, Lori E. Ross
openalex   +1 more source

Recent Developments in the Optical Control of Adrenergic Signaling

Medicinal Research Reviews, EarlyView.
ABSTRACT Adrenoceptors (ARs) play a vital role in various physiological processes and are key therapeutic targets. The advent of optical control techniques, including optogenetics and photopharmacology, offers the potential to modulate AR signaling with precise temporal and spatial resolution. In this review, we summarize the latest advancements in the
Shuang Shi, Yangzhi Cao, Maikel Wijtmans, Henry F. Vischer, Rob Leurs   +4 more
wiley   +1 more source

Delayed Dopamine Agonist Withdrawal Syndrome After Deep Brain Stimulation for Parkinson Disease. [PDF]

Neurol Clin Pract, 2021
Jackowiak EM, Chou KL, Patil PG, Levin E, Leventhal D.   +4 more
europepmc   +1 more source

The early treatment of Parkinson's disease: levodopa, dopamine agonists or both

, 2000
M. B. Stern
openalex   +1 more source

Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice [PDF]

, 2002
Rebecca J. Ralph-Williams, Virginia Lehmann-Masten, Veronica Otero-Corchón, Malcolm J. Low, Mark A. Geyer   +4 more
openalex   +1 more source